Johnson & Johnson (JNJ)

JNJ reported Q2 FY2026 revenue of $25.3B, up 6.6% year over year on 5.6% operational growth, while net income was essentially flat at $5.5B as STELARA biosimilar pressure, higher commercial spending, restructuring, and litigation-related charges offset broad product and MedTech growth. Source: 10-Q Item 2 MD&A, pp.32, 38-42; 10-Q Income Statement (XBRL).

营业收入

$25.31B

同比 +6.6%

净利润

$5.53B

同比 -0.1%

每股收益（稀释）

$2.27

同比 -0.9%

毛利率

68.2%

同比 +0.3pp